Kadcyla

The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate...


HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy...


T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab...


Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic...


Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people...


The College of American Pathologists ( CAP ) and the American Society of Clinical Oncology ( ASCO ) have issued...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


The FDA ( Food and Drug Administration ) has approved Kadcyla ( Trastuzumab Emtansine ), a new therapy for patients...